In 84% of CT scans with confirmed aortic valve calcium, radiology reports didn't mention it.
Nanox Imaging Ltd. (NASDAQ: NNOX) presented clinical data on its AI solution for detecting aortic valve calcification (AVC) at the TCT Conference. The HealthAVC solution demonstrated 98.3% sensitivity and 96.6% specificity in identifying AVC from routine CT scans, highlighting a significant gap in radiology reports. The study, published in JACC: Advances, analyzed 440 scans and found that 84.3% of AVC-positive cases were unreported.
How this was made
The 30-second read
Why it matters
The disclosed sensitivity and specificity suggest the AI could fill a diagnostic gap, potentially expanding Nanox's service offering and revenue streams.
Market read
First public data on Nanox's AI health product may influence investor perception of its growth prospects.
What to watch
Regulatory clearance timeline and reimbursement uncertainty could limit upside.
Background
Nanox Imaging (NASDAQ: NNOX) provides low-cost digital X‑ray hardware and AI analytics. The company unveiled new AI software that detects aortic valve calcium on routine chest CT scans.
Ticker impact
Nanox Imaging announced AI-based aortic valve calcification detection data with 98.3% sensitivity and 96.6% specificity.
likely upward pressure as investors price in AI product progress.
First disclosure of strong clinical performance may attract interest, but product is not yet cleared.
Market effects
Shows growing role of AI in medical imaging, may benefit broader imaging AI peers.
Limited to US biotech/medtech investors.
Modest, as AI health diagnostics gain attention worldwide.
Counterpoint
Product still unapproved; market may overreact to early data.
Key entities
- CompanyNanox Imaging Ltd.
US‑listed medical imaging and AI firm.
- SubsidiaryNanox.AI
AI unit developing the HealthAVC solution.
